Research Article
Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Table 2
Clinical characteristics of patients with tumor response and nonresponders.
| | | Responders (n = 10) | Nonresponder (n = 17) | value |
| | Age (year) | 56 (28.0 – 67.0) | 52 (32.0 – 60.0) | 0.269 | | Sex | 0.204 | | Male | 9 (90.0%) | 11 (64.7%) | | Female | 1 (10.0%) | 6 (35.3%) | | WBC count (×109/L) | 7.5 ± 0.5 | 7.9 ± 0.7 | 0.093 | | NE count (×109/L) | 5.2 ± 0.5 | 5.5 ± 0.7 | 0.033 | | Hgb (g/L) | 131.1 ± 5.6 | 136.4 ± 5.6 | 0.629 | | PLT count (×109/L) | 260.9 ± 35.0 | 253.1 ± 29.6 | 0.483 | | ALT (U/L) | 25.2 (14.8 – 53.8) | 23.3 (11.0 – 64.2) | 0.514 | | ALB (g/L) | 41.6 ± 1.7 | 42.7 ± 0.9 | 0.250 | | TBil (umol/L) | 13.8 ± 1.8 | 13.5 ± 1.4 | 0.999 | | PT (s) | 12.4 ± 0.3 | 12.1 ± 0.2 | 0.156 | | CRE (umol/L) | 75.6 ± 4.9 | 65.2 ± 3.7 | 0.967 | | AFP (ng/ml) | 9.5 (2.7 – 18,596.0) | 4.2 (1.1 – 91.7) | 0.035 | | CA19-9 (U/ml) | 17.85 (0.6 – 384.2) | 154.0 (0.7 – 20,000.0) | 0.016 | | CEA (ng/ml) | 3.0 (1.0 – 169.8) | 5.4 (1.1 – 63.3) | 0.874 | | HBsAg | 0.406 | | Negative | 2 (20.0%) | 7 (41.2%) | | Positive | 8 (80.0%) | 10 (58.8%) | | HBV-DNA | 0.018 | | ≤1 × 103 copies | 2 (20.0%) | 12 (70.6%) | | >1 × 103 copies | 8 (80.0%) | 5 (29.4%) | | Child–Pugh score | 0.370 | | 5 | 9 (90.0%) | 17 (100.0%) | | 6 | 1 (10.0%) | 0 (0.0%) | | Maximum diameter of tumor (cm) | 9.1 ± 1.1 | 8.0 ± 0.7 | 0.460 | | Tumor numbers | 0.257 | | Single | 6 (60.0%) | 6 (35.3%) | | Multiple | 4 (40.0%) | 11 (64.7%) | | Tumor distribution | 0.219 | | Unilobe | 5 (50.0%) | 13 (76.5%) | | Bilobe | 5 (50.0%) | 4 (23.5%) | | Macrovascular invasion | 0.415 | | Absent | 6 (60.0%) | 13 (76.5%) | | Present | 4 (40.0%) | 4 (23.5%) | | Distant metastasis | 0.230 | | Absent | 8 (80.0%) | 9 (52.9%) | | Present | 2 (20.0%) | 8 (47.1%) |
|
|
